This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Open Webinar Will Address Practical Aspects Of Drug Safety Perspective Of REMS Development

The practical aspects of utilizing a drug safety perspective in the development and implementation of Risk Evaluation and Mitigation Strategies (REMS) will be examined in a complimentary webinar for all interested parties this Wednesday, July 14, at 12 noon Eastern Time.

Entitled Considering a Drug Safety Perspective of REMS,” the program will also celebrate the second-half of the year-long, monthly webinar series “ Wednesday FoREMS” sponsored by ParagonRx, an inVentiv Health, Inc. company (NASDAQ:VTIV), and a leading consulting company specializing in pharmaceutical risk management and optimizing medication.

“Inherently, REMS is a cross-disciplinary activity, requiring the participation and insights of many functional groups to be successful,” says Jeffrey Fetterman, President of ParagonRx. “Each function has a unique perspective that is essential to designing and implementing an effective risk mitigation plan. This month we will delve into the Drug Safety perspective.”

Billy Holden, Chief Safety Officer of ParagonRx, will present a practical framework for quantitatively characterizing the benefit-risk profile of pharmaceutical products. Although all risk management is grounded in data arising from clinical trials and post marketing experience, too often the benefit-risk characterization and REMS design is qualitative in nature because risk and benefits are measured in different units, making a quantitative synthesis rather challenging.

Also presenting will be Rekha Garg, Executive Director of Risk Intervention Strategy and Communication at Amgen, who will discuss her company’s experiences leading the implementation of multiple REMS. She will share a model showing how a strongly centralized organization can functionally align with global safety, leading to a cross-functional implementation plan that requires the cooperation and commitment of many individuals across the company.

More information about registering for the “ Wednesday FoREMS” webinar series can be found at Webinars will be held the second Wednesday of each month at 12 noon EDT.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,667.24 -5.36 -0.03%
S&P 500 2,051.83 +0.01 0.00%
NASDAQ 4,756.7640 -1.1150 -0.02%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs